Identification

Name
Barbital
Accession Number
DB01483
Type
Small Molecule
Groups
Illicit
Description

A long-acting barbiturate that depresses most metabolic processes at high doses. It is used as a hypnotic and sedative and may induce dependence. Barbital is also used in veterinary practice for central nervous system depression. Barbital is a schedule IV controlled drug.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
5WZ53ENE2P
CAS number
57-44-3
Weight
Average: 184.1925
Monoisotopic: 184.08479226
Chemical Formula
C8H12N2O3
InChI Key
FTOAOBMCPZCFFF-UHFFFAOYSA-N
InChI
InChI=1S/C8H12N2O3/c1-3-8(4-2)5(11)9-7(13)10-6(8)12/h3-4H2,1-2H3,(H2,9,10,11,12,13)
IUPAC Name
5,5-diethyl-1,3-diazinane-2,4,6-trione
SMILES
CCC1(CC)C(=O)NC(=O)NC1=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
AGamma-aminobutyric acid receptor subunit alpha-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-4
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-5
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-6
potentiator
Human
UNeuronal acetylcholine receptor subunit alpha-4
antagonist
Human
UNeuronal acetylcholine receptor subunit alpha-7
antagonist
Human
UGlutamate receptor 2
antagonist
Human
UGlutamate receptor ionotropic, kainate 2
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Barbital is combined with 7-Nitroindazole.Experimental
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Barbital.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Barbital.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Barbital is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Barbital is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Barbital.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Barbital is combined with Adipiplon.Investigational
AgmatineThe metabolism of Agmatine can be increased when combined with Barbital.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Barbital is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Barbital is combined with Alaproclate.Experimental
AldesleukinBarbital may increase the hypotensive activities of Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Barbital is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Barbital.Approved, Illicit
AliskirenBarbital may increase the hypotensive activities of Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Barbital is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Barbital is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Barbital is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Barbital.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Barbital.Approved, Withdrawn
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Barbital.Experimental, Investigational
AmifostineBarbital may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideBarbital may increase the hypotensive activities of Amiloride.Approved
AmineptineThe metabolism of Amineptine can be increased when combined with Barbital.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Barbital.Approved
AmiodaroneBarbital may increase the hypotensive activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Barbital is combined with Amisulpride.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be increased when combined with Barbital.Approved
AmlodipineThe metabolism of Amlodipine can be increased when combined with Barbital.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Barbital.Approved, Illicit
AmoxapineThe metabolism of Amoxapine can be increased when combined with Barbital.Approved
AmperozideThe risk or severity of adverse effects can be increased when Barbital is combined with Amperozide.Experimental
Amphotericin BBarbital may increase the hypotensive activities of Amphotericin B.Approved, Investigational
AmrinoneThe metabolism of Amrinone can be increased when combined with Barbital.Approved
Amyl NitriteBarbital may increase the hypotensive activities of Amyl Nitrite.Approved
ApomorphineBarbital may increase the hypotensive activities of Apomorphine.Approved, Investigational
ApraclonidineBarbital may increase the hypotensive activities of Apraclonidine.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Barbital.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Barbital.Investigational
Arsenic trioxideBarbital may increase the hypotensive activities of Arsenic trioxide.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Barbital is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Barbital.Approved
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Barbital.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Barbital is combined with Azaperone.Investigational, Vet Approved
AzelastineBarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Barbital.Approved, Investigational
Azilsartan medoxomilBarbital may increase the hypotensive activities of Azilsartan medoxomil.Approved, Investigational
AzimilideThe metabolism of Azimilide can be increased when combined with Barbital.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Barbital.Approved
BarnidipineThe metabolism of Barnidipine can be increased when combined with Barbital.Approved
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Barbital.Experimental
BenazeprilBarbital may increase the hypotensive activities of Benazepril.Approved, Investigational
BencyclaneThe metabolism of Bencyclane can be increased when combined with Barbital.Experimental
BendroflumethiazideBarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved
BenidipineThe metabolism of Benidipine can be increased when combined with Barbital.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Barbital is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Barbital.Approved, Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Barbital is combined with Benzyl alcohol.Approved
BepridilThe metabolism of Bepridil can be increased when combined with Barbital.Approved, Withdrawn
BetaxololThe serum concentration of Betaxolol can be decreased when it is combined with Barbital.Approved, Investigational
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Barbital.Approved
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Barbital.Approved
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Barbital.Approved
BortezomibBarbital may increase the hypotensive activities of Bortezomib.Approved, Investigational
BretyliumBarbital may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Barbital.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Barbital.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Barbital is combined with Bromisoval.Experimental
BromocriptineBarbital may increase the hypotensive activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Barbital is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Barbital.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Barbital is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololThe serum concentration of Bucindolol can be decreased when it is combined with Barbital.Investigational
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Barbital.Experimental, Investigational
BumetanideBarbital may increase the hypotensive activities of Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Barbital.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Barbital.Approved
BuprenorphineBarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Barbital.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Barbital.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Barbital is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Barbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Barbital is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Barbital.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Barbital.Approved, Illicit, Vet Approved
CanagliflozinBarbital may increase the hypotensive activities of Canagliflozin.Approved
Candesartan cilexetilBarbital may increase the hypotensive activities of Candesartan cilexetil.Approved
CanertinibThe risk or severity of adverse effects can be increased when Barbital is combined with Canertinib.Investigational
CaptoprilBarbital may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Barbital.Approved, Investigational
CarbetocinBarbital may increase the hypotensive activities of Carbetocin.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Barbital.Approved
CarboxyamidotriazoleThe metabolism of Carboxyamidotriazole can be increased when combined with Barbital.Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Barbital is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Barbital.Approved
CaroverineThe metabolism of Caroverine can be increased when combined with Barbital.Experimental
CarteololThe serum concentration of Carteolol can be decreased when it is combined with Barbital.Approved
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Barbital.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Barbital.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Barbital.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Barbital is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolThe metabolism of Barbital can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Barbital.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Barbital.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Barbital.Approved
ChlorothiazideBarbital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe therapeutic efficacy of Chlorotrianisene can be decreased when used in combination with Barbital.Investigational, Withdrawn
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Barbital.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Barbital.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Barbital.Approved, Investigational, Withdrawn
ChlorthalidoneBarbital may increase the orthostatic hypotensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Barbital.Approved
CilazaprilBarbital may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe metabolism of Cilnidipine can be increased when combined with Barbital.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Barbital.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Barbital.Approved, Investigational
CitalopramThe risk or severity of adverse effects can be increased when Barbital is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Barbital.Approved, Investigational
ClevidipineThe metabolism of Clevidipine can be increased when combined with Barbital.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Barbital.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Barbital.Approved, Illicit
ClofarabineBarbital may increase the hypotensive activities of Clofarabine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Barbital is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Clomipramine can be increased when combined with Barbital.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Barbital.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Barbital.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Barbital is combined with Clopenthixol.Experimental
CloranololThe serum concentration of Cloranolol can be decreased when it is combined with Barbital.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Barbital.Approved, Illicit
ClorindioneThe metabolism of Clorindione can be increased when combined with Barbital.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Barbital is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Barbital.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Barbital.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Barbital.Approved, Illicit
ConivaptanBarbital may increase the hypotensive activities of Conivaptan.Approved, Investigational
Conjugated estrogensThe therapeutic efficacy of Conjugated estrogens can be decreased when used in combination with Barbital.Approved
CyclandelateThe metabolism of Cyclandelate can be increased when combined with Barbital.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Barbital.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be increased when combined with Barbital.Approved
CyclopenthiazideBarbital may increase the orthostatic hypotensive activities of Cyclopenthiazide.Experimental
CyclopropaneThe risk or severity of adverse effects can be increased when Barbital is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Barbital.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Barbital.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Barbital.Approved, Investigational
DapagliflozinBarbital may increase the hypotensive activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Barbital.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Barbital is combined with Dapoxetine.Investigational
DarodipineThe metabolism of Darodipine can be increased when combined with Barbital.Experimental
DeramciclaneThe risk or severity of adverse effects can be increased when Barbital is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Barbital.Approved
DesipramineThe metabolism of Desipramine can be increased when combined with Barbital.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Barbital.Approved, Investigational
DesogestrelThe therapeutic efficacy of Desogestrel can be decreased when used in combination with Barbital.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Barbital is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Barbital is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Barbital.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Barbital.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Barbital is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Barbital.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Barbital.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Barbital.Approved, Illicit, Investigational, Vet Approved
DibenzepinThe metabolism of Dibenzepin can be increased when combined with Barbital.Experimental
DiclofenamideBarbital may increase the hypotensive activities of Diclofenamide.Approved, Investigational
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Barbital.Approved
DienestrolThe therapeutic efficacy of Dienestrol can be decreased when used in combination with Barbital.Approved, Investigational
DienogestThe therapeutic efficacy of Dienogest can be decreased when used in combination with Barbital.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Barbital is combined with Diethyl ether.Experimental
DiethylstilbestrolThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Barbital.Approved, Investigational
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Barbital.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Barbital.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Barbital.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Barbital is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Diltiazem can be increased when combined with Barbital.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Barbital.Approved
DinutuximabBarbital may increase the hypotensive activities of Dinutuximab.Approved, Investigational
DiphenadioneThe metabolism of Diphenadione can be increased when combined with Barbital.Experimental
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Barbital.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Barbital.Approved, Illicit
DipyridamoleBarbital may increase the hypotensive activities of Dipyridamole.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Barbital is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Barbital is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Dosulepin can be increased when combined with Barbital.Approved
DotarizineThe metabolism of Dotarizine can be increased when combined with Barbital.Investigational
DoxazosinBarbital may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be increased when combined with Barbital.Approved, Investigational
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Barbital.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Barbital is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved, Vet Approved
DrospirenoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Barbital.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Barbital is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Barbital is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Barbital.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Barbital.Approved
EcgonineThe risk or severity of adverse effects can be increased when Barbital is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Barbital is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Barbital.Approved, Investigational
EfonidipineThe metabolism of Efonidipine can be increased when combined with Barbital.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Barbital is combined with Eltanolone.Investigational
EmpagliflozinBarbital may increase the hypotensive activities of Empagliflozin.Approved
EnalaprilBarbital may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatBarbital may increase the hypotensive activities of Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Barbital.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Barbital.Approved, Investigational
EpanololThe serum concentration of Epanolol can be decreased when it is combined with Barbital.Experimental
EperisoneThe metabolism of Eperisone can be increased when combined with Barbital.Approved, Investigational
EplerenoneBarbital may increase the hypotensive activities of Eplerenone.Approved
EpoprostenolBarbital may increase the hypotensive activities of Epoprostenol.Approved
EprosartanBarbital may increase the hypotensive activities of Eprosartan.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Barbital is combined with Escitalopram.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Barbital.Investigational
EsmololThe serum concentration of Esmolol can be decreased when it is combined with Barbital.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Barbital.Approved, Illicit
EstradiolThe therapeutic efficacy of Estradiol can be decreased when used in combination with Barbital.Approved, Investigational, Vet Approved
EstramustineThe therapeutic efficacy of Estramustine can be decreased when used in combination with Barbital.Approved, Investigational
Estrogens, esterifiedThe therapeutic efficacy of Estrogens, esterified can be decreased when used in combination with Barbital.Approved
Estrone sulfateThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Barbital.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Barbital.Approved, Investigational
Etacrynic acidBarbital may increase the hypotensive activities of Etacrynic acid.Approved, Investigational
EthanolBarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Barbital.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Barbital.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Barbital.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Barbital.Approved
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Barbital.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Barbital is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Barbital is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Barbital is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Barbital.Approved, Illicit
Ethynodiol diacetateThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Barbital.Approved
EtidocaineThe risk or severity of adverse effects can be increased when Barbital is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Barbital is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Barbital is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Barbital.Approved
EtonogestrelThe therapeutic efficacy of Etonogestrel can be decreased when used in combination with Barbital.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Barbital is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Barbital is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Barbital.Approved, Investigational
FelbamateThe serum concentration of Barbital can be increased when it is combined with Felbamate.Approved
FelodipineThe metabolism of Felodipine can be increased when combined with Barbital.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Barbital.Approved, Illicit, Withdrawn
FendilineThe metabolism of Fendiline can be increased when combined with Barbital.Withdrawn
FenoldopamBarbital may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Barbital.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Barbital.Approved, Investigational
FimasartanBarbital may increase the hypotensive activities of Fimasartan.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Barbital.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Barbital is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Barbital is combined with Fludiazepam.Approved, Illicit
FluindioneThe metabolism of Fluindione can be increased when combined with Barbital.Approved, Investigational
FlunarizineThe metabolism of Flunarizine can be increased when combined with Barbital.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Barbital is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Barbital is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Barbital.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Barbital.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Barbital.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Barbital is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Barbital.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Barbital.Approved, Investigational
FosinoprilBarbital may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Barbital.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Barbital is combined with Fospropofol.Approved, Illicit, Investigational
FurosemideBarbital may increase the hypotensive activities of Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Barbital.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Barbital.Approved, Investigational
GallopamilThe metabolism of Gallopamil can be increased when combined with Barbital.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Barbital.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Barbital is combined with Gepirone.Investigational
GestodeneThe therapeutic efficacy of Gestodene can be decreased when used in combination with Barbital.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Barbital.Approved, Illicit
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Barbital.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Barbital.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Barbital.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Barbital.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Barbital.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Barbital.Approved, Illicit, Investigational
HexestrolThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Barbital.Withdrawn
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Barbital.Approved
HydralazineBarbital may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideBarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneBarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideBarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Barbital.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Barbital.Approved
IloprostBarbital may increase the hypotensive activities of Iloprost.Approved, Investigational
ImidaprilBarbital may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be increased when combined with Barbital.Approved
IndalpineThe risk or severity of adverse effects can be increased when Barbital is combined with Indalpine.Investigational, Withdrawn
IndapamideBarbital may increase the orthostatic hypotensive activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Barbital.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Barbital is combined with Indiplon.Investigational
IndoraminBarbital may increase the hypotensive activities of Indoramin.Withdrawn
IprindoleThe metabolism of Iprindole can be increased when combined with Barbital.Experimental
IrbesartanBarbital may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidBarbital may increase the hypotensive activities of Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Barbital.Approved, Vet Approved
Isosorbide DinitrateBarbital may increase the hypotensive activities of Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateBarbital may increase the hypotensive activities of Isosorbide Mononitrate.Approved
IsoxsuprineBarbital may increase the hypotensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Isradipine can be increased when combined with Barbital.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Barbital.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Barbital is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Barbital is combined with Ketobemidone.Approved, Investigational
LabetalolThe serum concentration of Labetalol can be decreased when it is combined with Barbital.Approved
LacidipineThe metabolism of Lacidipine can be increased when combined with Barbital.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Barbital.Approved, Investigational
LandiololThe serum concentration of Landiolol can be decreased when it is combined with Barbital.Investigational
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Barbital.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Barbital.Approved, Investigational
LevobunololThe serum concentration of Levobunolol can be decreased when it is combined with Barbital.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Barbital.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Barbital is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Barbital.Approved
LevodopaBarbital may increase the hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Barbital.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Barbital is combined with Levomilnacipran.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Barbital.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Barbital.Approved
LevosimendanBarbital may increase the hypotensive activities of Levosimendan.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Barbital.Approved, Vet Approved
LidoflazineThe metabolism of Lidoflazine can be increased when combined with Barbital.Experimental
LisinoprilBarbital may increase the hypotensive activities of Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Barbital.Approved
LofentanilThe risk or severity of adverse effects can be increased when Barbital is combined with Lofentanil.Illicit
LofepramineThe metabolism of Lofepramine can be increased when combined with Barbital.Experimental
LofexidineBarbital may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoperamideThe metabolism of Loperamide can be increased when combined with Barbital.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Barbital is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Barbital.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Barbital.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Barbital is combined with Lormetazepam.Approved
LosartanBarbital may increase the hypotensive activities of Losartan.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Barbital.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Barbital.Approved, Investigational
LynestrenolThe therapeutic efficacy of Lynestrenol can be decreased when used in combination with Barbital.Approved, Investigational
Magnesium SulfateThe therapeutic efficacy of Barbital can be increased when used in combination with Magnesium Sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Manidipine can be increased when combined with Barbital.Approved, Investigational
MannitolBarbital may increase the hypotensive activities of Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Barbital.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Barbital is combined with Mebicar.Experimental
MecamylamineBarbital may increase the hypotensive activities of Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Barbital.Approved
MedazepamThe risk or severity of adverse effects can be increased when Barbital is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Barbital is combined with Medetomidine.Vet Approved
MedrogestoneThe serum concentration of Medrogestone can be decreased when it is combined with Barbital.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Barbital.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Barbital.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Barbital is combined with Melperone.Approved, Investigational
MepindololThe serum concentration of Mepindolol can be decreased when it is combined with Barbital.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Barbital.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Barbital.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Barbital is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Barbital.Approved, Investigational
MestranolThe therapeutic efficacy of Mestranol can be decreased when used in combination with Barbital.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Barbital.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Barbital.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Barbital.Approved, Illicit
MethallenestrilThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Barbital.Experimental
MethapyrileneThe risk or severity of adverse effects can be increased when Barbital is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Barbital is combined with Methaqualone.Illicit, Withdrawn
MethazolamideBarbital may increase the hypotensive activities of Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Barbital.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Barbital.Approved
MethotrimeprazineBarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Barbital.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Barbital.Approved
MethyclothiazideBarbital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
MethyldopaBarbital may increase the hypotensive activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Barbital is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Barbital.Approved
MetipranololThe serum concentration of Metipranolol can be decreased when it is combined with Barbital.Approved
MetolazoneBarbital may increase the orthostatic hypotensive activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Barbital.Approved, Investigational
MetyrosineBarbital may increase the sedative activities of Metyrosine.Approved
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved, Investigational
MibefradilThe metabolism of Mibefradil can be increased when combined with Barbital.Investigational, Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Barbital.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Barbital is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved, Investigational
MinoxidilBarbital may increase the hypotensive activities of Minoxidil.Approved, Investigational
MirtazapineBarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoexiprilBarbital may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Barbital is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Barbital.Approved, Investigational
MoxonidineBarbital may increase the hypotensive activities of Moxonidine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved, Investigational
NadololThe serum concentration of Nadolol can be decreased when it is combined with Barbital.Approved
NaftopidilThe metabolism of Naftopidil can be increased when combined with Barbital.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Barbital.Approved
NebivololThe serum concentration of Nebivolol can be decreased when it is combined with Barbital.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Barbital is combined with Nefazodone.Approved, Withdrawn
NesiritideBarbital may increase the hypotensive activities of Nesiritide.Approved, Investigational
NicardipineThe metabolism of Nicardipine can be increased when combined with Barbital.Approved, Investigational
NifedipineThe metabolism of Nifedipine can be increased when combined with Barbital.Approved
NiguldipineThe metabolism of Niguldipine can be increased when combined with Barbital.Experimental
NiludipineThe metabolism of Niludipine can be increased when combined with Barbital.Experimental
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Barbital.Approved, Investigational
NimesulideThe metabolism of Nimesulide can be increased when combined with Barbital.Approved, Investigational, Withdrawn
NimodipineThe metabolism of Nimodipine can be increased when combined with Barbital.Approved, Investigational
NisoldipineThe metabolism of Nisoldipine can be increased when combined with Barbital.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Barbital.Approved
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Barbital.Approved, Investigational
Nitric OxideBarbital may increase the hypotensive activities of Nitric Oxide.Approved
NitroglycerinBarbital may increase the hypotensive activities of Nitroglycerin.Approved, Investigational
NitroprussideBarbital may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Barbital.Approved, Vet Approved
NorelgestrominThe therapeutic efficacy of Norelgestromin can be decreased when used in combination with Barbital.Approved, Investigational
NorfluraneThe risk or severity of adverse effects can be increased when Barbital is combined with Norflurane.Approved, Investigational
NorgestimateThe therapeutic efficacy of Norgestimate can be decreased when used in combination with Barbital.Approved, Investigational
NorgestrelThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Barbital.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Barbital is combined with Normethadone.Approved, Illicit
NortriptylineThe metabolism of Nortriptyline can be increased when combined with Barbital.Approved
ObinutuzumabBarbital may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Barbital.Approved, Investigational
OlmesartanBarbital may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Barbital.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Barbital.Approved
OpipramolThe metabolism of Opipramol can be increased when combined with Barbital.Investigational
OpiumThe risk or severity of adverse effects can be increased when Barbital is combined with Opium.Approved, Illicit
OrphenadrineBarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Barbital is combined with Osanetant.Investigational
OtiloniumThe metabolism of Otilonium can be increased when combined with Barbital.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Barbital.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Barbital is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Barbital is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Barbital.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Barbital.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Barbital.Approved, Investigational, Vet Approved
PaclitaxelBarbital may increase the hypotensive activities of Paclitaxel.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Barbital.Approved
PapaverineBarbital may increase the hypotensive activities of Papaverine.Approved, Investigational
ParaldehydeBarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Barbital is combined with Paroxetine.Approved, Investigational
PenbutololThe serum concentration of Penbutolol can be decreased when it is combined with Barbital.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Barbital is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Barbital.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Barbital.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved
PerazineThe risk or severity of adverse effects can be increased when Barbital is combined with Perazine.Approved, Investigational
PerindoprilBarbital may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Barbital is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Barbital.Approved
PethidineBarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Barbital is combined with Phenazocine.Experimental
PhenelzineBarbital may increase the hypotensive activities of Phenelzine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Barbital is combined with Phenibut.Experimental
PhenindioneThe metabolism of Phenindione can be increased when combined with Barbital.Approved, Investigational
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Barbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Barbital is combined with Phenoperidine.Experimental
PhenoxybenzamineBarbital may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Barbital is combined with Phenoxyethanol.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Barbital.Approved, Investigational
PhentolamineBarbital may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Barbital.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Barbital.Approved
PinaveriumThe metabolism of Pinaverium can be increased when combined with Barbital.Approved
PindololThe serum concentration of Pindolol can be decreased when it is combined with Barbital.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Barbital is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Barbital.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Barbital is combined with Piritramide.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Barbital.Approved
Platelet Activating FactorThe serum concentration of Platelet Activating Factor can be decreased when it is combined with Barbital.Experimental
PolythiazideBarbital may increase the orthostatic hypotensive activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Barbital.Approved
PractololThe serum concentration of Practolol can be decreased when it is combined with Barbital.Approved
PramipexoleBarbital may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Barbital is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Barbital is combined with Prazepam.Approved, Illicit
PrazosinBarbital may increase the hypotensive activities of Prazosin.Approved
PregabalinThe therapeutic efficacy of Barbital can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe metabolism of Prenylamine can be increased when combined with Barbital.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Barbital.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Barbital.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Barbital.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Barbital.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Barbital.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Barbital.Approved, Investigational
PropacetamolThe metabolism of Propacetamol can be increased when combined with Barbital.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Barbital is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Barbital.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Barbital.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Barbital is combined with Propoxycaine.Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Barbital.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be increased when combined with Barbital.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Barbital is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Barbital is combined with PSD502.Investigational
PyridoxineThe metabolism of Barbital can be increased when combined with Pyridoxine.Approved, Investigational, Nutraceutical, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Barbital.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Barbital.Approved
QuinaprilBarbital may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinethazoneBarbital may increase the orthostatic hypotensive activities of Quinethazone.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Barbital is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Barbital is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Barbital.Approved, Investigational
RamiprilBarbital may increase the hypotensive activities of Ramipril.Approved
RasagilineBarbital may increase the hypotensive activities of Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Barbital.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Barbital.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Barbital.Approved, Investigational
RifabutinThe metabolism of Barbital can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Barbital can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Barbital can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Barbital can be increased when combined with Rifaximin.Approved, Investigational
RiociguatBarbital may increase the hypotensive activities of Riociguat.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Barbital.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Barbital is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Barbital is combined with Romifidine.Vet Approved
RopiniroleBarbital may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Barbital.Approved
RotigotineBarbital may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Barbital.Approved
SacubitrilBarbital may increase the hypotensive activities of Sacubitril.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Barbital.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Barbital.Approved, Vet Approved
SelegilineBarbital may increase the hypotensive activities of Selegiline.Approved, Investigational, Vet Approved
SeletracetamThe metabolism of Seletracetam can be increased when combined with Barbital.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Barbital is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Barbital is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Barbital is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Barbital.Approved, Vet Approved
Sodium NitriteBarbital may increase the hypotensive activities of Sodium Nitrite.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Barbital.Approved, Investigational
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Barbital.Approved
SpironolactoneBarbital may increase the hypotensive activities of Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Barbital.Approved
StreptokinaseBarbital may increase the hypotensive activities of Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Barbital.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Barbital.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Barbital is combined with Sultopride.Experimental
SuvorexantBarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
Synthetic Conjugated Estrogens, AThe therapeutic efficacy of Synthetic Conjugated Estrogens, A can be decreased when used in combination with Barbital.Approved
TalinololThe serum concentration of Talinolol can be decreased when it is combined with Barbital.Investigational
TamsulosinBarbital may increase the hypotensive activities of Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Barbital is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Barbital.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Barbital.Approved, Investigational
TelmisartanBarbital may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Barbital.Approved, Investigational
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Barbital.Approved
TerazosinBarbital may increase the hypotensive activities of Terazosin.Approved
TerodilineThe metabolism of Terodiline can be increased when combined with Barbital.Experimental
TertatololThe serum concentration of Tertatolol can be decreased when it is combined with Barbital.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Barbital.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Barbital is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Barbital is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Barbital is combined with Tetrodotoxin.Investigational
ThalidomideBarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Barbital.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Barbital.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Barbital.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Barbital.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Barbital.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Barbital.Approved, Investigational
TianeptineThe metabolism of Tianeptine can be increased when combined with Barbital.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Barbital is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Barbital is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Barbital is combined with Tilidine.Experimental
TimololThe serum concentration of Timolol can be decreased when it is combined with Barbital.Approved
TioclomarolThe metabolism of Tioclomarol can be increased when combined with Barbital.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Barbital.Approved, Investigational
TolazolineBarbital may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeBarbital may increase the hypotensive activities of Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Barbital.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Barbital.Approved
TorasemideBarbital may increase the hypotensive activities of Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Barbital.Approved, Investigational
TrandolaprilBarbital may increase the hypotensive activities of Trandolapril.Approved
TranilastThe metabolism of Tranilast can be increased when combined with Barbital.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Barbital is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Barbital.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Barbital.Approved, Investigational
TretinoinBarbital may increase the hypotensive activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneBarbital may increase the hypotensive activities of Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Barbital.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Barbital is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideBarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Barbital is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Barbital.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Barbital is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Barbital.Approved, Vet Approved
TrimebutineThe metabolism of Trimebutine can be increased when combined with Barbital.Approved
TrimethadioneThe metabolism of Trimethadione can be increased when combined with Barbital.Approved
TrimipramineThe metabolism of Trimipramine can be increased when combined with Barbital.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Barbital.Approved
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Barbital.Approved
Valproic AcidThe serum concentration of Barbital can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanBarbital may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Barbital is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Barbital is combined with Veralipride.Experimental
VerapamilThe metabolism of Verapamil can be increased when combined with Barbital.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Barbital.Approved
VinpocetineThe metabolism of Vinpocetine can be increased when combined with Barbital.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Barbital is combined with Vinyl ether.Experimental
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Barbital.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Barbital is combined with Vortioxetine.Approved, Investigational
WarfarinThe metabolism of Warfarin can be increased when combined with Barbital.Approved
WIN 55212-2The metabolism of WIN 55212-2 can be increased when combined with Barbital.Experimental
XenonThe risk or severity of adverse effects can be increased when Barbital is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Barbital is combined with Xylazine.Vet Approved
XylometazolineThe metabolism of Xylometazoline can be increased when combined with Barbital.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Barbital.Approved, Illicit, Investigational
ZiconotideThe metabolism of Ziconotide can be increased when combined with Barbital.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Barbital is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Barbital.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Barbital is combined with Zolazepam.Vet Approved
ZolpidemBarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Barbital.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Barbital.Approved
ZotepineThe risk or severity of adverse effects can be increased when Barbital is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Barbital.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C02517
PubChem Compound
2294
PubChem Substance
46508979
ChemSpider
2206
ChEBI
31252
ChEMBL
CHEMBL444
Therapeutic Targets Database
DAP001350
PharmGKB
PA448538
Wikipedia
Barbital
ATC Codes
N05CA04 — Barbital

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)190 °CPhysProp
boiling point (°C)250 °C at 2.20E+01 mm HgPhysProp
water solubility7460 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.65HANSCH,C ET AL. (1995)
logS-1.39ADME Research, USCD
pKa8.14 (at 15 °C)KORTUM,G ET AL (1961)
Predicted Properties
PropertyValueSource
Water Solubility3.23 mg/mLALOGPS
logP0.73ALOGPS
logP0.72ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)8.48ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity44.25 m3·mol-1ChemAxon
Polarizability17.59 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.955
Blood Brain Barrier+0.9694
Caco-2 permeable-0.6146
P-glycoprotein substrateNon-substrate0.5238
P-glycoprotein inhibitor INon-inhibitor0.7826
P-glycoprotein inhibitor IINon-inhibitor0.9964
Renal organic cation transporterNon-inhibitor0.9395
CYP450 2C9 substrateNon-substrate0.7915
CYP450 2D6 substrateNon-substrate0.9074
CYP450 3A4 substrateNon-substrate0.7823
CYP450 1A2 substrateNon-inhibitor0.896
CYP450 2C9 inhibitorNon-inhibitor0.9436
CYP450 2D6 inhibitorNon-inhibitor0.9586
CYP450 2C19 inhibitorNon-inhibitor0.918
CYP450 3A4 inhibitorNon-inhibitor0.9723
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9847
Ames testAMES toxic0.5531
CarcinogenicityNon-carcinogens0.8532
BiodegradationNot ready biodegradable0.9462
Rat acute toxicity3.5489 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9913
hERG inhibition (predictor II)Non-inhibitor0.9734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (8.31 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - CI-BGC-MSsplash10-000i-0900000000-90fb45d882d2c3ed038f
GC-MS Spectrum - EI-BGC-MSsplash10-052f-9400000000-fa1289872f9f35015abc
GC-MS Spectrum - EI-BGC-MSsplash10-052f-9500000000-856a7fe5dbfd28d00c38
GC-MS Spectrum - EI-BGC-MSsplash10-0a4l-2900000000-42c0874d0bac13cc2d94
GC-MS Spectrum - EI-BGC-MSsplash10-0a4u-5900000000-497f9ee367181a6df30a
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Barbituric acid derivatives
Alternative Parents
N-acyl ureas / Diazinanes / Dicarboximides / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Barbiturate / N-acyl urea / Ureide / 1,3-diazinane / Dicarboximide / Urea / Carbonic acid derivative / Carboxylic acid derivative / Azacycle / Organic nitrogen compound
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
barbiturates (CHEBI:31252)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
  3. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  4. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA2
Uniprot ID
P47869
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-2
Molecular Weight
51325.85 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA3
Uniprot ID
P34903
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-3
Molecular Weight
55164.055 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA4
Uniprot ID
P48169
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-4
Molecular Weight
61622.645 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Transporter activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA5
Uniprot ID
P31644
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-5
Molecular Weight
52145.645 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA6
Uniprot ID
Q16445
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-6
Molecular Weight
51023.69 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
  2. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
Gene Name
CHRNA4
Uniprot ID
P43681
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-4
Molecular Weight
69956.47 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Toxic substance binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The cha...
Gene Name
CHRNA7
Uniprot ID
P36544
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-7
Molecular Weight
56448.925 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Ionotropic glutamate receptor activity
Specific Function
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory ne...
Gene Name
GRIA2
Uniprot ID
P42262
Uniprot Name
Glutamate receptor 2
Molecular Weight
98820.32 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Kainate selective glutamate receptor activity
Specific Function
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a co...
Gene Name
GRIK2
Uniprot ID
Q13002
Uniprot Name
Glutamate receptor ionotropic, kainate 2
Molecular Weight
102582.475 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]

Drug created on July 31, 2007 07:09 / Updated on February 02, 2018 01:15